All regulations
Nonrulemaking
FDA
FDA-2025-P-4150
Request that the FDA declare that Lactulose for Oral Solution, 15 gPacket, is suitable for submission as an ANDA. As designated in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), the Reference Listed Drug (“RLD”) upon which this petition is based is Sanofi Aventis US’s Chronulac (lactulose) oral solution, which was approved for prescription use
Documents
14
Comments
0
Description
CLOSED
Key Dates
Comment Period OpensSep 23, 2025
Documents
| Type | Title | Status |
|---|---|---|
Other |
Keywords
CDER
Suitability Petition
Lactulose for Oral Solution, 15 g/Packet
suitable for submission as an ANDA
Approved Drug Products with Therapeutic
Equivalence Evaluations (Orange Book)
Reference Listed Drug (RLD)
upon which this petition is based is
Data from Regulations.gov